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and the pharmaceutical implications are vast: for example, the development of a widely
used type of antihypertensive agent, angiotensin-converting enzyme inhibitors, derived
from snake venom research.
Grenard is to be commended on his succinct thoroughness and attention to detail.
Every organism is identified by its common and taxonomic name. Facts are quantitative
rather than qualitative wherever possible. The bibliography, researched by David Katz, is
extensive and very much up to date. It is only unfortunate that not more than two authors
are listed for every reference.
The only major criticism that I hold against MedicalHerpetology is its lack ofobjec-
tive criticism towards much of the research presented. Conclusions are often more opti-
mistic than warranted. The author's enthusiasm for herpetology's impact on human med-
icine gives the reader the impression that every research avenue is likely to yield a major
breakthrough. History and common sense tell us that this is not so. Happily, when one is
intrigued but skeptical about something mentioned, many relevant citations will direct the
curious to the primary sources ofcontroversy.
Medical Herpetology is a book full offacts and figures that range from the clinically
relevant to minutiae medica, from important investigations to cocktail-party fare. It is
original, scholarly and fulfills its mandate entirely, although it may at times test your
credulity (e.g., the Australian Gastric Brooding Frog). The book is highly recommended
to physicians, scientists and students fascinated by, or even only curious about, these
underrated animals. As the author puts it, the book is "..the logical culmination of [...]
medical and herpetological interests." I am grateful to budding herpetologist Dane
Trembath for bringing it to my attention.
Kevin F. Kwaku
M.D./Ph.D. Student
Columbia University
AN INTRODUCTION TO GENETIC ENGINEERING. By Desmond S.T. Nicholl.
Cambridge, United Kingdom, Cambridge University Press, 1994. 168 pp, illustrated.
$39.95 hardcover, $16.95 paperback.
With the ever-increasing number of recombinant DNA methods, newcomers to the
field may become overwhelmed by the proliferation ofterminology and techniques. This
book sets out to demystify a full range ofgenetic engineering technology developed over
the past twenty years. Beginning with a basic introduction to DNA structure, it quickly
moves into more advanced topics such as plasmid and bacteriophage vectors. Subsequent
chapters describe cloning strategies, including polymerase chain reaction (PCR), and
screening techniques such as restriction mapping and Southern blotting. The last chapter
concerning current examples of gene manipulation-transgenic plants and chimeric ani-
mals-makes for particularly fascinating reading.
The book's purpose is to be brief, yet all-encompassing, in its survey. Its structure
reflects that purpose: a few paragraphs for each technique or technology. There is a sur-
prising amount ofdetail found in each section, such as a debate over the benefits ofusing
pBR322 versus pAT153 as cloning plasmids. On the other hand, many major topics such
as PCRandrestriction fragment length polymorphisms receive short-shrift as they are del-
egated only a couple ofparagraphs each. The basic concepts ofeach technique, however,
are described adequately and clearly, with a fine section on suggestions for further read-
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Recommended for incoming undergraduate students, the book provides a quick
understanding ofthe important terms and techniques forcurrentDNA-relatedresearch. Its
utility for medical students, however, is somewhat limited by its brevity and enormous
scope. At almost $40 in hardcover, the book is far too expensive. At $16.95 in softcover,
it remains somewhat less so, but may be worth the cost for a rapid introduction to genet-
ic engineering.
Jersey Chen
Medical Student
Yale University School ofMedicine
ADVERSE EVENTS ASSOCIATED WITH CHILDHOOD VACCINES: EVIDENCE
BEARING ON CAUSALITY. Edited by Kathleen R. Stratton, Cynthia J. Howe and
Richard B. Johnson, Jr. Washington, D.C., NationalAcademy Press, 1993. 464 pp. $49.95.
This report, prepared by the Vaccine Safety Committee, Division of Health
Promotion and Disease Prevention, Institute of Medicine, is a careful and exhaustive
review ofevidence from the scientific literature and from adverse event surveillance sys-
tems, concerning causal relationships, or lack thereof, between each adverse experience
(AE) and the vaccine that preceded it. It supplements a companion volume (Adverse
Effects ofPertussis and Rubella Vaccines) and addresses AE issues related to diphtheria
and tetanus (T) toxoids (or DT for children and Td for adults if combined), measles,
mumps, polio (OPV and IPV), hepatitis B and Hemophilus influenzae type b vaccines.
Evidence on causality of AEs is categorized into five classes, including: no evidence,
inadequate evidence, evidence favoring rejection, evidence favoring acceptance or evi-
dence establishing a causal relationship with the given vaccine. Special analyses are
included ofthe evidentiary basis for causality, ofthe varieties ofneurologic and immuno-
logic reactions and of post-vaccination death. The last chapter reviews areas most need-
ing additional research and enhanced surveillance.
Most ofthe serious AEs reviewed are rare, a fact that poses some difficulty in assess-
ing causality, since rare serious AEs are typically far less often reported after vaccination
compared to the population at large. Additional difficulty arises from the paucity ofcon-
trolled trial data, a deficiency often impossible to remedy, given the huge populations
needed to ensure detection of such rare events. The majority of the data, based on case
reports and uncontrolled observational studies, is therefore appropriately graded as inde-
terminate by the committee. The rarity of the most serious AEs, especially compared to
adverse outcomes caused by the respective diseases prevented by vaccination, points to
the immense societal benefit in relation to the rare risk of serious harm associated with
mass vaccination with these vaccines.
Key findings include evidence favoring rejection of causal linkage between
encephalopathy, sudden infant death syndrome (SIDS) or infantile spasms and DT or Td
(or T separately) and between early onset H. influenzae b disease and related conjugate
vaccines. Evidence wasjudged to favor acceptance ofcausality between DT, Td or T and
brachial neuritis or Guillain-Barre syndrome, between measles vaccine and anaphylactic
reactions, between OPV and Guillain-Barre and between early onset H. influenzae b dis-
ease in children under 18 months old and previous vaccination with unconjugated PRP
vaccine. Causality established by the evidence was determined foranaphylaxis following
DT, Td or T; thrombocytopenia, anaphylaxis or measles virus-related death (in the
immunocompromised) after measles vaccination; recipient or contact polio or related
death after OPV; and anaphylaxis after hepatitis B vaccination.